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Abstract
Introduction: Men who have sex with men (MSM) and transgender women (TGW) in Brazil experience high rates of HIV
infection. We examined the clinical and economic outcomes of implementing a pre-exposure prophylaxis (PrEP) programme in
these populations.
Methods: We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International model of HIV prevention
and treatment to evaluate two strategies: the current standard of care (SOC) in Brazil, including universal ART access (No
PrEP strategy); and the current SOC plus daily tenofovir/emtracitabine PrEP (PrEP strategy) until age 50. Mean age (31 years,
SD 8.4 years), age-stratified annual HIV incidence (age ≤ 40 years: 4.3/100 PY; age > 40 years: 1.0/100 PY), PrEP effective-
ness (43% HIV incidence reduction) and PrEP drug costs ($23/month) were from Brazil-based sources. The analysis focused
on direct medical costs of HIV care. We measured the comparative value of PrEP in 2015 United States dollars (USD) per year
of life saved (YLS). Willingness-to-pay threshold was based on Brazil’s annual per capita gross domestic product (GDP; 2015:
$8540 USD).
Results: Lifetime HIV infection risk among high-risk MSM and TGW was 50.5% with No PrEP and decreased to 40.1% with
PrEP. PrEP increased per-person undiscounted (discounted) life expectancy from 36.8 (20.7) years to 41.0 (22.4) years and life-
time discounted HIV-related medical costs from $4100 to $8420, which led to an incremental cost-effectiveness ratio (ICER)
of $2530/YLS. PrEP remained cost-effective (<1x GDP) under plausible variation in key parameters, including PrEP effective-
ness and cost, initial cohort age and HIV testing frequency on/off PrEP.
Conclusion: Daily tenofovir/emtracitabine PrEP among MSM and TGW at high risk of HIV infection in Brazil would increase
life expectancy and be highly cost-effective.
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1 | INTRODUCTION
A growing body of evidence supports the use of tenofovir/em-
tracitabine pre-exposure prophylaxis (PrEP) to prevent HIV
infection, particularly in high-risk populations. A 2016 meta-
analysis of 18 PrEP-related studies conducted in high-risk
populations demonstrated that PrEP reduces HIV infection
risk in men who have sex with men (MSM), transgender
women (TGW), injection drug users, and other high-risk
populations [1]. Moreover, pooled results from the same study
showed that PrEP did not increase adverse event rates com-
pared to no PrEP, nor did it result in risk compensation among
PrEP users. These results support the World Health Organiza-
tion’s (WHO) 2014 recommendation for PrEP use in high-risk
populations [2].
In Brazil, the HIV epidemic is concentrated in vulnerable
populations. Incidence in these groups has increased in the
past decade, particularly in young adults in the past five years
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[3]. Recent estimates by the Department of STIs, AIDS and
Viral Hepatitis of the Brazilian Ministry of Health report an
HIV prevalence of 0.4% in the general population [3]. This fig-
ure is much higher among MSM, ranging from 5.2% to 23.7%
[4]. In addition to prevalence, HIV incidence is also elevated
among MSM, estimated as >6 infections per 100 person-years
in 2006 [5]. Recent national data suggest that the already sev-
ere epidemic among MSM is growing. In 2007, 30.8% of those
newly diagnosed with HIV infection reported sex with other
men as the mode of HIV acquisition; by 2016, this proportion
reached 50.2% [3]. HIV risk is even more pronounced among
TGW [6]; in Rio de Janeiro, Brazil, their HIV prevalence is
estimated at 31.2% [7].
Curbing the rising HIV burden among MSM and TGW in
Brazil will require the development of targeted prevention
programmes, such as an HIV PrEP programme. PrEP efficacy
in Brazil was evaluated in an international randomized con-
trolled trial [8], and the potential implementation of PrEP
was also assessed in “PrEP Brasil,” a local demonstration pro-
ject [9]. These studies indicated that PrEP use in high-risk
MSM would be clinically beneficial in Brazil, and our goal
was to evaluate the long-term clinical benefits and cost-effec-
tiveness of such an intervention. Prior modelling studies have
evaluated the cost-effectiveness of PrEP use among MSM
and other high-risk individuals in other countries [10,11].
Ours is a nation-specific analysis of daily tenofovir/em-
tracitabine PrEP use in MSM and TGW at high risk of HIV
in Brazil using the best available epidemiological, clinical, and
economic data.
2 | METHODS
2.1 | Analytic overview
We used the Cost-Effectiveness of Preventing AIDS Compli-
cations (CEPAC)-International model, a widely published
model of HIV disease and treatment [12-14], to project the
clinical benefits and economic impact of daily tenofovir/
emtricitabine (TDF/FTC)-based PrEP until age 50 for adult
HIV-uninfected (age ≥18 years) MSM and TGW at high risk
of HIV infection. We examined two strategies: standard of
care with no PrEP (No PrEP) and standard of care with
PrEP (PrEP). Key outcomes included lifetime HIV infection
risk, life expectancy (LE), lifetime HIV-related medical cost,
and incremental cost-effectiveness ratio (ICER) in dollars per
year of life saved (YLS). We conducted sensitivity analyses
to examine the robustness of our results to parameter varia-
tion. We measured the comparative value of PrEP in 2015
United States dollars (USD) per YLS. In conformity with
accepted practice [15], all economic outcomes were assessed
from the perspective of the Brazilian National Health Sys-
tem. We applied widely accepted conventions with regard to
discounting, accounting for time preferences by weighing
costs and health outcomes less heavily the further into the
future they occur. Economic outcomes were discounted at
an annual rate of 3%, while clinical outcomes were reported
on both a discounted and undiscounted basis. We excluded
medical care costs not related to HIV/AIDS. We defined a
strategy as “cost-effective” if its ICER was less than the
Brazilian annual per capita gross domestic product (GDP;
2015: $8540 USD).
2.2 | Model overview
2.2.1 | Disease module
CEPAC-I is a state-transition Monte Carlo simulation model of
HIV infection, detection, disease and treatment. All individuals
are tracked from model entry until death, regardless of HIV sta-
tus. The Disease module of CEPAC-I simulates disease treat-
ment and progression among HIV-infected individuals. Upon
infection, individuals enter the Disease module of CEPAC-I,
receive an initial CD4 count, and experience disease progres-
sion according to user-defined HIV-related opportunistic infec-
tion (OI) risks and mortality. Model users can define a wide
variety of screening and treatment parameters, including HIV
screening practices (occasional or routine testing), ART efficacy
and toxicity, HIV care practices regarding clinic visits and labora-
tory monitoring, as well as OI prophylaxis and treatment. Suc-
cessful ART decreases HIV viral load and increases CD4 count,
which leads to reduced mortality from OIs or chronic AIDS. The
model also tracks costs for HIV treatment, medication and mon-
itoring; non-HIV-related costs are excluded.
2.2.2 | HIV testing and PrEP module
In this module, uninfected individuals are assigned initial charac-
teristics, including age and sex at birth (male only for this analy-
sis), and then face user-specifiable monthly probabilities of HIV
infection that vary by age. PrEP is simulated as a reduction in
HIV infection probability and has associated medication (TDF/
FTC) and HIV testing costs. Individuals can be tested for HIV in
two ways: through “background” HIV testing randomly occur-
ring at a specific monthly probability, or through more frequent,
regular testing. PrEP is discontinued either when an individual
reaches age 50 or if an individual is infected with HIV and
detected through testing or a clinically observed OI; upon
detection, individuals transition to the Disease Module
described above. Key parameters pertaining to the implementa-
tion of PrEP are provided in Table 1 and in the Supplementary
Materials. A comprehensive technical description of the CEPAC
Model is available online at http://www.massgeneral.org/
mpec/cepac/. Specifically, the PrEP model description can be
found at http://www.massgeneral.org/MPEC/Assets/Files/Upda
tedFiles/Pre-Exposure%20Prophylaxis%20_PrEP_.pdf.
2.3 | Cohort and strategies
We simulated HIV-uninfected MSM and TGW at high risk of
HIV infection in Brazil, modelling them as one population. While
TGW experience a higher disease burden than MSM in Brazil
[7], we combined the two populations because a PrEP pro-
gramme in Brazil would likely target both. In the No PrEP strat-
egy, individuals faced a monthly risk of HIV infection and were
randomly tested for HIV at a rate of 4.4% per year (correspond-
ing to a ~50% expected probability of being tested at least once
over a lifetime) as per testing rates observed in this population
in Brazil. We examined higher background testing rates in sensi-
tivity analyses. In the PrEP strategy, HIV-uninfected individuals
received PrEP from simulation start, HIV testing every four
months, and annual creatinine testing until HIV infection and
subsequent detection if infected. Upon diagnosis, all HIV-
infected and detected individuals in both strategies received
Luz PM et al. Journal of the International AIDS Society 2018, 21:e25096
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25096/full | https://doi.org/10.1002/jia2.25096
2
HIV treatment concordant with Brazil’s guidelines, including
immediate ART initiation regardless of CD4 count [16].
2.4 | Model input data
2.4.1 | Demographic characteristics and natural history
Demographic data used to characterize the simulated cohort
were based on PrEP Brasil, a multicentre, open-label PrEP
demonstration project assessing PrEP implementation for
MSM and TGW at high risk of HIV infection within the Brazil-
ian public health system [9,17]. For the purposes of the pre-
sent analysis, we followed the definitions adopted in the PrEP
Brasil study and defined high risk as any of the following
behaviours in the prior 12 months: condomless anal sex with
≥2 partners, ≥2 episodes of anal sex with an HIV-infected
partner, or history of STD diagnosis. Individuals entering the
simulation were assigned an age based on a random draw
from a distribution with mean 31.4 years and standard devia-
tion 8.4 years. Individuals became eligible for PrEP when they
attained 18 years of age. Mean CD4 count at HIV infection
was 559/lL [18,19]. Monthly OI risks, as well as mortality
risks attributable to HIV, were derived from the HIV-infected
cohort of the Instituto Nacional de Infectologia Evandro Cha-
gas, Fundac~ao Oswaldo Cruz, in Rio de Janeiro, Brazil [20].
2.4.2 | HIV incidence rate
HIV incidence rates without PrEP were 4.3 per 100 PY
(<40 years) and 1.0 per 100 PY (≥40 years) [21].
2.4.3 | PrEP effectiveness
We defined PrEP effectiveness as a multiplicative composite
of three component factors:
Table 1. Select model input parameters
Variable
Base case
value
Range in
sensitivity
analysis References
Baseline cohort characteristic
Age, years, mean (SD) 31.4 (8.4) 26.4 to 36.4 [40]
Annual HIV incidence, by age, infections/100 PY
≤40 years 4.3 2.1 to 6.4 [21]
>40 years 1 0.1 to 2.0 [21]
PrEP characteristics
PrEP effectiveness, %
incidence reduction
43.2 21.6 to 64.8
PrEP efficacy 96 [23,24]
PrEP uptake 61 [17]
PrEP adherence 73.9 [22]
HIV testing characteristics
Frequency of HIV test
receipt on PrEP, tests/
y
3 2 to 4 [41]
Background testing rate,
tests/100 PY
4.4 2.2 to 11.4 [42]
Clinical characteristics post-HIV infection
Acute CD4 count, cells/
µL, mean (SD)
559 (236) 419 to 699 [18,19]
ART characteristics
Initial first-line
suppression, %
90 85 to 95 [43]
Rate of virologic failure,
instances/100 PM
0.2 [44,45]
Increase in CD4 count
after 48 weeks on
suppressive ART, cells/
µL, mean (SD)
196 (49) [43]
PrEP-associated costs
PrEP drug cost, $/year 270a 135 to 405* [25]
HIV test cost, $/test 1.57b 0.79 to 3.14 [46]
Clinic visit cost, $/visit 3.73 [47]
Creatinine testing cost,
$/year
0.69 [47]
Antiretroviral therapy cost, $/year
First line:
EFV+TDF+3TC
120a 72 to 120 [46]
Second line: LPV/
r+TDF+3TC
932 559 to 932 [46]
Third line: RAL+DRV/
r+2 NRTI
6119 3671 to 6119 [46]
Fourth line: ETR+PI/r+2
NRTI
5549 3330 to 5549 [46]
Fifth line: MVC+PI/r+2
NRTI
3558 2135 to 3558 [46]
HIV viral load test, per
test, $
14.36 7.18 to 21.54 [48]
CD4 count test, $/test 13.57 6.79 to 20.36 [48]
Table 1. (Continued)
Variable
Base case
value
Range in
sensitivity
analysis References
Routine care cost
conditional on CD4
count, $/month
3.88 to
43.66
0.5x to 1.5x
base case costs
[47]
Annual discount rate, % 3 [15]
SD, standard deviation; MSM, men who have sex with men; TGW,
transgender women; HIV, human immunodeficiency virus; PY, person-
years; PrEP, pre-exposure prophylaxis; ART, antiretroviral treatment;
PM, person-months; EFV, efavirenz; TDF, tenofovir disoproxil fuma-
rate; 3TC, lamivudine; LPV/r, lopinavir/ritonavir; RAL, raltegravir; DRV/
r, darunavir/ritonavir; NRTI, nucleoside reverse transcriptase inhibitor;
ETR, etravirine; PI/r, protease inhibitor/ritonavir; MVC, maraviroc.
aIn the Supplementary Material, we consider a range of PrEP drug
costs from 0.5x to 1.5x and 2x the base case value.
bFirst-line ART drug costs assume fixed-dose, generic combinations of
TDF + EFV + 3TC. PrEP drug costs, in contrast, assume branded for-
mulations of TDF/FTC.
cApplies only to HIV testing in the PrEP strategy since background
testing rate/cost are identical in both the No PrEP and PrEP scenarios.
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• PrEP uptake (i.e. the proportion of the eligible population
who accepted the offer of PrEP). We used uptake result
from PrEP Brasil of 60.9% [17].
• Adherence (i.e. the proportion of those receiving PrEP
whose pharmacokinetic profiles are consistent with 4 or
more doses/week). We used week-48 adherence estimate
from PrEP Brasil of 73.9% [22].
• Efficacy (i.e. the performance of PrEP in idealized settings
where uptake and adherence can be assumed to be close
to 100%). We used efficacy estimates of 96% as derived by
a pharmacokinetic model and recently confirmed with
directly observed therapy [23,24].
We multiplied these point estimates (60.9%*73.9%*96.0%)
to get a base case effectiveness value of 43.2%. We then con-
ducted sensitivity analyses on this base case estimate to
explore the effects of uncertainty in the uptake of PrEP, the
adherence to PrEP, and the pharmacologic efficacy of FTC/
TDF. We considered PrEP effectiveness values ranging from
0.5 to 1.5 times the base case (21.6% to 64.8%) in order to
ensure a wide interval for the effectiveness parameter.
2.4.4 | ART regimens and laboratory monitoring
As per Brazilian national guidelines [16], five sequential ART
lines were available in the simulation: first-line ART included
efavirenz, tenofovir and lamivudine, second-line was protease
inhibitor-based, and the remaining three salvage lines included
integrase inhibitors and second-generation non-nucleoside
reverse transcriptase inhibitors. A recent meta-analysis
showed that most cases of drug-resistant HIV infection
occurred among PrEP users who initiated PrEP while acutely
HIV infected, and that the incidence of acquiring drug-resis-
tant HIV during PrEP use was negligible [1]; we therefore
assumed PrEP users who became HIV infected used the same
ART lines as those who did not use PrEP. Moreover, we did
not consider PrEP-induced ART resistance in the base case
PrEP scenario though its impact was explored in sensitivity
analyses. HIV-infected people were monitored with CD4 tests
every six months and HIV RNA two months after initiation of
each ART line and every six months thereafter.
2.4.5 | Costs
The largest component of PrEP costs was the cost of teno-
fovir/emtricitabine, which we assumed to be $22.5/month in
the base case, as per official contract by the Brazilian Ministry
of Health [25]. In the Supplementary Material, we also report
on 0.5x ($11.25/month) given that lower costs have been
reported in the PAHO strategic fund website, as well as upper
values of 1.5x ($33.75/month) and 2x ($45/month). We also
factored in PrEP programme costs, including clinic visits/coun-
selling every four months ($3.73), HIV testing every four
months ($1.57), and annual creatinine testing ($0.69). Since
the Brazilian NHS makes no provision for an incremental
adherence counselling intervention alongside the PrEP pro-
gramme, we assume that the costs of adherence counselling
are included in the costs of the clinic visit every four months.
HIV tests, administered every four months to persons
receiving PrEP, cost $1.57 per test. CD4 and HIV viral load
test costs ($13.57 and $14.36) were from the Department of
STIs, AIDS and Viral Hepatitis, Ministry of Health (Table 1).
Annual ART costs ranged from $120 for first-line ART to
$6119 for third-line ART; a genotype resistance testing cost
of $132 was applied every time an ART regimen was changed.
OI treatment costs were from Instituto Nacional de Infectolo-
gia Evandro Chagas, Fundac~ao Oswaldo Cruz.
2.5 | Sensitivity analyses
To assess the robustness of our results, we examined the
impact of varying key inputs over a wide range of values; these
included average cohort age at model entry, PrEP effectiveness
and cost, HIV incidence, age at PrEP discontinuation (including
the possibility of lifetime PrEP), and HIV background testing
rate. We also examined the impact of ART resistance in a sensi-
tivity analysis where we reduced the efficacy of first- and sec-
ond-line ART by 10% for patients who acquired HIV while on
PrEP. Although some studies have suggested an increase in
adverse events (e.g. renal toxicity [26] and reduction in bone
mineral density [27]) for individuals using tenofovir-based
PrEP, a recent meta-analysis showed that adverse event rates
were not different for those on and off PrEP in 10 placebo-
controlled randomized trials [1]. For this reason, we did not
include the risk of PrEP-related adverse events in the base
case scenario. Finally, we considered multi-way analyses to
examine outcomes influenced by simultaneous variation in
those variables found to be most influential in the one-way
sensitivity analyses described previously.
3 | RESULTS
3.1 | Base case
3.1.1 | Clinical
Compared to No PrEP, PrEP increased remaining undiscounted
(discounted) life expectancy from 36.8 (20.7) years to 41.0
(22.4) years, or by 4.2 (1.7) years (Table 2).
PrEP reduced per-person lifetime (and five-year) HIV
infection risk from 50.5% (16.2%) to 40.1% (9.7%). PrEP
also increased the speed with which new cases of HIV
infection were detected and linked to care. Average CD4
count at detection was 432 cells/mL under PrEP and
238 cells/mL under No Prep. Owing to both its prevention
effects and its rapid linkage of breakthrough infections
to care, PrEP reduced the probability of dying of HIV-
related causes from simulation start from 1.3% to 0.3%
over five years, and from 22.3% to 11.1% over a lifetime
(Table 2).
3.1.2 | Costs
Total costs over five years under PrEP are $890/person
compared to $47/person for No PrEP. Over a lifetime, costs
under the PrEP strategy are more than double those of No
PrEP ($8420 vs. $4100 per person). Thirty-eight percent of
the costs under PrEP are attributable to prophylaxis medica-
tion and testing (Figure 1). Again, as shown previously,
although it reduces lifetime risks of HIV infection, PrEP also
produces more rapid detection and linkage to care and,
consequently, expected lifetime costs of HIV treatment (ART
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and routine care) are higher in the PrEP arm than in the
No PrEP arm. Overall outlays for ART, for example, increase
from $3400 to $4610 per person. Because new infections
are detected earlier, the costs of OI treatment are lower
with PrEP.
3.1.3 | Cost-effectiveness
Discounted lifetime per-person HIV-related medical costs
increased from $4100 with No PrEP to $8420 with PrEP
(Table 2). The ICER of PrEP compared to No PrEP was $2530/
YLS, ~30% of Brazil’s 2015 GDP per capita of $8540.
3.2 | Sensitivity analyses
We re-evaluated our assessment using the data ranges specified
in Table 1. Our overall finding was that PrEP remains cost-effec-
tive in the face of all plausible uncertainty in the input parameters
(Figure 2). Importantly, variation in the ART-related parameters
such as annual ART cost per HIV-infected person, initial suppres-
sion of ART regimens, and CD4 and viral load monitoring costs, as
well as others, had minimal impact on the ICER for PrEP. Similarly,
the cost and frequency of HIV testing – whether as a component
of the PrEP intervention or as background screening in the at-risk
population – had only minimal impact on the ICER for PrEP and
no impact on the overall cost-effectiveness finding. The ICER was
virtually unchanged (varying <$200/YLS) when we modified the
baseline PrEP duration assumption from discontinuation at age
50 to lifetime use. When we varied average PrEP start age
between 26.4 and 36.4, the variation in the ICER for PrEP
amounted to ~$1000/YLS. When we assumed that PrEP-induced
resistance would cause first- and second-line ART to be 10% less
effective, the ICER of PrEP compared to No PrEP increased by
$500/YLS, to $3100/YLS. There was no substantial change in the
ICER for PrEP when we lowered the minimum cohort age from
18 to 15. In the subsections that follow, we note a small number
of instances where varying the input assumptions had an informa-
tive qualitative effect on the output.
3.2.1 | PrEP drug cost
At higher PrEP drug costs, such as $33.75/month (1.5x base case
cost), PrEP was still cost-effective: $3300/YLS. PrEP remained
cost-effective until PrEP drug costs exceeded $100/month.
3.2.2 | HIV incidence
Varying the HIV incidence in the population over its plausible
range, from 2.1 infections per 100 PY to 6.4 infections per
100 PY, resulted in ICERs of $2100/YLS to $4100/YLS. PrEP
was no longer cost-effective at incidence rates as low as 0.9
per 100 PY (0.2x base case incidence). At very high incidence
of 21 infections per 100 PY (5x base case incidence), PrEP’s
ICER was lower, at $2070/YLS.
3.2.3 | PrEP effectiveness
Assuming effectiveness at 0.5 (21.6%) and 1.5 (64.8%) times
the base case value (43.2%) led to ICERs of $3140/YLS and
$1830/YLS respectively. PrEP-associated costs accounted for
a larger proportion of total strategy cost as effectiveness
increased, both because other costs (such as routine care
costs and ART costs) decreased and because duration of PrEP
use increased.
Table 2. Base case results of analysis of PrEP cost-effective-
ness in Brazil
No PrEP PrEP
Undiscounted per-person life expectancya, y 36.8 41.0
Five-year HIV infection riskb, % 16.2 9.7
Lifetime HIV infection riskb, % 50.5 40.1
Five-year averted HIV infectionsc, % – 6.5
Lifetime averted HIV infectionsc, % – 10.5
Five-year HIV-attributable deathsd, % 1.3 0.3
Lifetime HIV-attributable deathsd, % 22.3 11.1
Undiscounted five-year coste, $ 50 940
Discounted five-year coste, $ (3%) 50 890
Undiscounted lifetime coste, $ 10,910 19,070
Discounted per-person life expectancya, y (3%) 20.7 22.4
Discounted lifetime coste, $ (3%) 4100 8420
ICER, Dcost/DLE – 2530
PrEP, pre-exposure prophylaxis; y, years; HIV, human immunodefi-
ciency virus; ICER, incremental cost-effectiveness ratio measured by
change in 2015 US dollars (Dcost) per change in life expectancy
(DLE).
aLife expectancy was defined from start of simulation.
bHIV infection risk was calculated by dividing the number of infections
by the initial cohort size.
cAverted HIV infections were calculated by subtracting the number of
infections in the No PrEP strategy by the number of infections in the
PrEP strategy.
dHIV attributable death was based on the number of deaths due to
HIV related causes among those who were HIV-infected.
eCost outcomes are rounded to the nearest $10.
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Figure 1. Strategy-specific cost breakdown. Average discounted
per-person cost of No PrEP (left) and PrEP (right) strategies strati-
fied by component: ART for treatment; routine care; opportunistic
infections and death; and PrEP (drug and monitoring). PrEP: pre-
exposure prophylaxis, OI: opportunistic infection, ART: antiretro-
viral therapy. Note that background testing costs remain the same
under both strategies and are not reported here.
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3.2.4 | PrEP effectiveness, HIV incidence and PrEP
drug cost
We simultaneously varied PrEP effectiveness, HIV incidence
and PrEP drug cost across wide ranges (Figure 3 and Fig-
ure S1). PrEP remained cost-effective compared to No PrEP in
all scenarios with incidence ranging from 1.7 to 8.8 infections
per 100 PY, effectiveness ranging from 22% to 64.8%, and
drug cost of $22.5 or $33.75/month. At base case cost
($22.5) PrEP was not cost-effective compared to No PrEP
when incidence fell to 0.4 infections per 100 PY for effective-
ness ranging from 22% to 64.8%.
4 | DISCUSSION
We evaluated the clinical benefits, costs and cost-effective-
ness of PrEP use to prevent HIV infection in MSM and TGW
at high risk of HIV infection in Brazil. We found that a PrEP
strategy would substantially reduce five-year and lifetime risk
of HIV infection. Compared to standard of care, we found that
PrEP was highly cost-effective by GDP standards, with an
ICER of $2530/YLS (~30% of Brazil’s 2015 per capita GDP,
$8540). We also found that PrEP would remain cost-effective
unless PrEP drug costs exceeded $1200/year ($100/month).
In one-way sensitivity analyses, we found that varying
parameter values within plausible ranges yielded ICERs that
were lower than Brazil’s GDP per capita, suggesting that our
conclusions are robust to uncertainty in our input data values.
In the base case scenario, PrEP was no longer cost-effective if
HIV incidence was less than 0.4 per 100 PY (<10% of base
case value). Prior research has suggested that HIV incidence
among MSM around the globe far surpasses this threshold,
and is likely higher among young MSM [5]. For PrEP effective-
ness, the lowest value assessed (22% effectiveness) still indi-
cated that PrEP was cost-effective. Even when assuming
worst-case estimates for PrEP drug cost of $45 per month,
the ICER of PrEP was of $4300 per YLS, half of Brazil’s GDP
per capita. PrEP acts both as prevention against new infections
and as a detection and linkage tool for the cases of infection
that it fails to prevent. Because of this, PrEP is creating not
only new prevention costs, but also increasing the costs of
care. Indeed, our results show that ART costs under PrEP are
even higher than in the No PrEP strategy (Figure 1). Though
PrEP is more costly than No PrEP, both the prevention pro-
vided by PrEP and the earlier detection and linkage to care
for infections that are not prevented leads to more years of
life saved and is ultimately cost-effective.
This is the first analysis to use simulation modelling to esti-
mate the cost-effectiveness of a PrEP programme in Brazil. One
analysis investigating the use of PrEP in Peruvian MSM and
TGW found that the highest estimated cost per disability
adjusted life-year averted was below Peru’s GDP per capita,
assuming PrEP use by 20% of MSM and TGW [28]. In our analy-
sis, we based PrEP uptake on the results of the PrEP Brasil
demonstration project, which showed that 61% of the eligible
population chose to initiate PrEP [17]. In addition, we assumed
adherence to the drugs as observed in this project. We found
that with this level of uptake and adherence, PrEP led to a cost
per life-year saved that was well below Brazil’s GDP per capita.
Other analyses examining the value of PrEP among MSM in
concentrated epidemics in high-income countries found that
Figure 2. One-way sensitivity analyses. The tornado diagram displays the sensitivity of the incremental cost-effectiveness ratio (ICER) of
PrEP compared to No PrEP to variation in a large number of input parameter values. For each input parameter on the vertical axis, base case
values are listed first, followed by the range considered in sensitivity analysis. The range values are ordered: the value yielding the lowest
ICER in sensitivity analysis is listed first; the value yielding the highest ICER in sensitivity analysis is listed second. GDP: gross domestic pro-
duct per capita, PrEP: pre-exposure prophylaxis, ART: antiretroviral therapy.
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PrEP was cost-saving or cost-effective [10,29,30]. In the United
States, providing PrEP to MSM at high risk for HIV infection
would yield an ICER of $50,000 per quality adjusted life year,
making it cost-effective by US standards [10]. Another analysis
considering both the US and Peru looked at main and casual
partnerships and found that targeting men in casual partner-
ships could increase PrEP’s efficiency [31]. Our results reinforce
the value of PrEP for populations at high risk of HIV infection
and suggest that one of the challenges to PrEP delivery will be
the process of risk assessment by clinicians. In this regard, it is
encouraging that an open-label extension study [32] as well as
PrEP Brasil [9] both found that men at higher risk of HIV infec-
tion are both more willing to use PrEP and more adherent. Nev-
ertheless, studies measuring behaviour over time show wide
variation, such that clinicians will need to continually re-evaluate
high-risk behaviour [33].
Our results should be interpreted with caution. A finding of
cost-effectiveness indicates a favourable return on investment
but cannot definitively address the affordability of PrEP. A
recent review of PrEP analyses [18] highlights the need for
future studies to consider the budget impact of PrEP implemen-
tation. Our analysis has a number of other limitations. Though
we have used the most recent estimate of HIV incidence
derived from a multi-site international trial, which is consistent
with published prevalence estimates [4] and with model derived
cumulative risk, HIV incidence estimates for Brazil’s MSM and
TGW at high risk of HIV population are scarce. We conducted
extensive sensitivity analyses and found that our conclusions
were robust to HIV incidence; PrEP was not cost-effective when
incidence was at 0.4 infections per 100 PY (<10% base case
incidence). Nevertheless, PrEP implementation and coverage
may modify HIV incidence such that research into HIV inci-
dence in different populations will become more important. The
No PrEP strategy assumed current levels of ART uptake,
although it is plausible that Brazil’s current test and treat strat-
egy could lead to earlier ART uptake in future years, which in
turn could decrease HIV incidence. However, the current HIV
care cascade among MSM suggests that MSM and TGW are
not experiencing major improvements in access to care in Brazil
[5,34], likely due to high levels of stigma and discrimination. A
recent analysis from our cohort suggested that, contrary to
what was observed in heterosexual men, the increased risk of
AIDS-related deaths among MSM could not be explained by
immunological and clinical factors associated with AIDS mortal-
ity, again suggesting that stigma and discrimination might be
important barriers to care for this population [35]. Indeed,
stigma and discrimination could also represent important barri-
ers for PrEP uptake, and, if that were the case, there could be
additional costs associated with diminishing barriers and
increasing demand that we have excluded. Fortunately, though
PrEP-related stigma has emerged as a social harm that can arise
from PrEP research participation/use, the PrEP Brasil study
found that only 4.6% of its participants reported social harms
[22]. In this analysis, we accounted only for first-generation,
age-dependent HIV transmission to uninfected MSM and TGW
at high risk of HIV infection and therefore did not include any
second-order benefits that PrEP will provide. Including sec-
ondary transmission would make PrEP even more cost-effective.
Our analysis also does not take into consideration the potential
savings that could be enjoyed by limiting PrEP use to periods
(or ages) when individuals are at highest risk/susceptibility for
HIV infection [36,37]. Taking such “seasons of risk” into account
could further strengthen the case for expanded PrEP. The pre-
sent study combined MSM and TGW into one population given
the scarcity of data regarding TGW in our setting. These
assumptions should be revised and the analysis refined when
TGW-specific data become available, though the high HIV bur-
den among TGW suggests conclusions would not change. We
restricted our study population to MSM and TGW aged
18 years or older because this population would likely be the
first offered PrEP. However, Brazil’s expanding HIV epidemic
among MSM younger than 18 years led us to explore a scenario
where minimum cohort age was 15 years. While progress has
been made to estimate preference-based weights for health
states based on a representative sample of the Brazilian popula-
tion [38], data are not yet available to support the use of qual-
ity-adjusted life years in this analysis. Readers should note,
therefore, that our definition of “cost-effective” used an ICER
Figure 3. Sensitivity analysis: PrEP effectiveness and HIV incidence. A heat map displays the incremental cost-effectiveness ratio (ICER) of
PrEP compared to No PrEP as PrEP effectiveness and HIV incidence are simultaneously varied. PrEP effectiveness increases from left to right
across the horizontal axis; HIV incidence decreases up the vertical axis. Combinations of PrEP effectiveness and HIV incidence that result in
PrEP being cost-saving, cost-effective, and not cost-effective compared to No PrEP are displayed in blue, green, and orange, respectively.
The boldface X in the figure denotes the base case values for PrEP effectiveness and HIV incidence. PrEP: pre-exposure prophylaxis, GDP:
gross domestic product per capita.
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measured in dollars per year of life saved and not in more com-
monly recommended measures that account for the quality of
life [39]. Finally, the possibility of generic manufacturing of TDF/
FTC as well as the adoption of branded drugs for ART (such as
the dolutegravir for first-line regimen [16]) could modify the
results generated in the present study against and for PrEP
respectively.
5 | CONCLUSION
Our cost-effectiveness findings support immediate expansion
of investment in combination prevention to include PrEP in
MSM and TGW populations at the highest risk for HIV infec-
tion in Brazil. They also justify further study of the budget
impact of PrEP implementation. Our results show that HIV
incidence is the major determinant of PrEP cost-effectiveness
and thus merits future monitoring. In the present scenario of
increasing HIV incidence among young MSM and TGW, PrEP
implementation, in the context of a combination prevention
framework, including HIV testing as well as ART adherence
interventions, will be cost-effective.
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